| |
Velpatasvir-Based Regimens in Treatment-Naïve and Treatment-Experienced Adults with Resistant HCV GT4 Subtypes Endemic to Sub-Saharan Africa
Findings from the SHARED-3 Study in Rwanda
|
| |
| |
Presenting Author: Dr. Fabienne Shumbusho
Other Authors: Fredrick Kateera, Linda Manirambona, Jules Kabihizi, Anthere Murangwa, Janvier Serumondo, Jean Damascene Makuza, Sabin Nsanzimana, Claude Muvunyi, Emmanuel Musabeyezu, Greg Camus, Philip M Grant, Neil Gupta
AASLD: RARE HCV GENOTYPES: PREVALENCE AND RESISTANCE-ASSOCIATED SUBSTITUTIONS IN DAA-NAÏVE AND DAA-EXPERIENCED PATIENTS (12/01/21)
AASLD: LONG-TERM PERSISTENCE OF RESISTANCE-ASSOCIATED SUBSTITUTIONS (RASS) AFTER DAA TREATMENT FAILURE IN PATIENTS WITH CHRONIC HCV INFECTION (12/01/21)
AASLD: Treat HCV Early; SOF/DCV Had Lower SVR Rates (11/30/21)
| |
| |
| |
|
|
|
